Global Oncolytic Virus Market Growth (Status and Outlook) 2023-2029

Global Oncolytic Virus Market Growth (Status and Outlook) 2023-2029

An oncolytic virus is a virus that preferentially infects and kills cancer cells. As the infected cancer cells are destroyed by oncolysis, they release new infectious virus particles or virions to help destroy the remaining tumor. Oncolytic Virus Therapy is an exciting, increasingly recognized discipline in cancer research. Although the connection between viruses and cancer regression was recognized in the early 20th century, it wasn’t until the recent development of advanced genetic engineering techniques that true progress has been made using virotherapy to attack and destroy cancer cells. Today, researchers can modify existing viruses to create new oncolytic viruses that are less susceptible to immune suppression while more specifically targeting particular classes of cancer cells. Additionally, these modified oncolytic viruses can be adapted to insert and express cancer-suppressing genes and diagnostic proteins.
LPI (LP Information)' newest research report, the “Oncolytic Virus Industry Forecast” looks at past sales and reviews total world Oncolytic Virus sales in 2022, providing a comprehensive analysis by region and market sector of projected Oncolytic Virus sales for 2023 through 2029. With Oncolytic Virus sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Oncolytic Virus industry.
This Insight Report provides a comprehensive analysis of the global Oncolytic Virus landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Oncolytic Virus portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Oncolytic Virus market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Oncolytic Virus and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Oncolytic Virus.
The global Oncolytic Virus market size is projected to grow from US$ 17 million in 2022 to US$ 27 million in 2029; it is expected to grow at a CAGR of 7.1% from 2023 to 2029.
To date, two genetically engineered oncolytic viruses have been approved for marketing as drugs. One is Oncorine (H101, the same construct as ONYX‐015),9 an E1B‐deleted adenovirus, which was approved in China for head and neck cancer and esophagus cancer in 2005. The use and clinical data of Oncorine is so far limited to China. The other is T‐Vec (talimogene laherparepvec, IMLYGIC, formerly OncoVEXGM‐CSF), which was approved for melanoma by the FDA in the USA in October 2015 and was subsequently approved in Europe in January 2016 and in Australia in May 2016. For developing product, there are 3 products in Phase 3, 8 products in Phase 2, 7 products in Phase 1 and 3 products in Preclinical. Market competition is intense. Amgen, Shanghai Sunway Biotech, Oncolytics Biotech, Viralytics, Transgene SA are the leading developers in the industry; with high investment in research marketing and they will monopoly position in the industry. Other players include Oncolys BioPharma, Targovax, PsiOxus Therapeutics, SillaJen Biotherapeutics, Sorrento Therapeutics, Lokon Pharma, Genelux Corporation, Vyriad, TILT Biotherapeutics and Cold Genesys, etc.
This report presents a comprehensive overview, market shares, and growth opportunities of Oncolytic Virus market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Imlygic
Oncorine
Others
Segmentation by application
Melanoma
Other Cancers
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Amgen
Shanghai Sunway Biotech

Please note: The report will take approximately 2 business days to prepare and deliver.